| pubmed-article:19499960 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19499960 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19499960 | lifeskim:mentions | umls-concept:C0020538 | lld:lifeskim |
| pubmed-article:19499960 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:19499960 | lifeskim:mentions | umls-concept:C0051696 | lld:lifeskim |
| pubmed-article:19499960 | lifeskim:mentions | umls-concept:C0386393 | lld:lifeskim |
| pubmed-article:19499960 | lifeskim:mentions | umls-concept:C0442805 | lld:lifeskim |
| pubmed-article:19499960 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:19499960 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:19499960 | pubmed:dateCreated | 2009-6-8 | lld:pubmed |
| pubmed-article:19499960 | pubmed:abstractText | Hypertension remains a major global health problem, and evidence suggests that the majority of patients will require two or more antihypertensive agents in order to reach specified BP targets. Combining two drugs from different classes has the potential to target different aspects of hypertension, which may result in additional BP decreases compared with either agent used alone. This randomized, double-blind, parallel-group, multicentre trial in patients with moderate-to-severe hypertension (systolic BP [SBP]/diastolic BP [DBP] > or =160/100 mmHg) investigated the additional efficacy in BP reduction and BP goal rates (<140/90 mmHg for patients without diabetes mellitus, <130/80 mmHg for patients with diabetes) achieved by adding amlodipine 5 or 10 mg/day to olmesartan medoxomil (hereafter olmesartan) 20 mg/day in patients not adequately controlled on olmesartan monotherapy. | lld:pubmed |
| pubmed-article:19499960 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19499960 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19499960 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19499960 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19499960 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19499960 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19499960 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19499960 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19499960 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19499960 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19499960 | pubmed:issn | 1173-2563 | lld:pubmed |
| pubmed-article:19499960 | pubmed:author | pubmed-author:HongI SIS | lld:pubmed |
| pubmed-article:19499960 | pubmed:author | pubmed-author:BarriosVivenc... | lld:pubmed |
| pubmed-article:19499960 | pubmed:author | pubmed-author:CalderónAlber... | lld:pubmed |
| pubmed-article:19499960 | pubmed:author | pubmed-author:EscobarCarlos... | lld:pubmed |
| pubmed-article:19499960 | pubmed:author | pubmed-author:BrommerPeterP | lld:pubmed |
| pubmed-article:19499960 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:19499960 | pubmed:volume | 29 | lld:pubmed |
| pubmed-article:19499960 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19499960 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19499960 | pubmed:pagination | 427-39 | lld:pubmed |
| pubmed-article:19499960 | pubmed:meshHeading | pubmed-meshheading:19499960... | lld:pubmed |
| pubmed-article:19499960 | pubmed:meshHeading | pubmed-meshheading:19499960... | lld:pubmed |
| pubmed-article:19499960 | pubmed:meshHeading | pubmed-meshheading:19499960... | lld:pubmed |
| pubmed-article:19499960 | pubmed:meshHeading | pubmed-meshheading:19499960... | lld:pubmed |
| pubmed-article:19499960 | pubmed:meshHeading | pubmed-meshheading:19499960... | lld:pubmed |
| pubmed-article:19499960 | pubmed:meshHeading | pubmed-meshheading:19499960... | lld:pubmed |
| pubmed-article:19499960 | pubmed:meshHeading | pubmed-meshheading:19499960... | lld:pubmed |
| pubmed-article:19499960 | pubmed:meshHeading | pubmed-meshheading:19499960... | lld:pubmed |
| pubmed-article:19499960 | pubmed:meshHeading | pubmed-meshheading:19499960... | lld:pubmed |
| pubmed-article:19499960 | pubmed:meshHeading | pubmed-meshheading:19499960... | lld:pubmed |
| pubmed-article:19499960 | pubmed:meshHeading | pubmed-meshheading:19499960... | lld:pubmed |
| pubmed-article:19499960 | pubmed:meshHeading | pubmed-meshheading:19499960... | lld:pubmed |
| pubmed-article:19499960 | pubmed:meshHeading | pubmed-meshheading:19499960... | lld:pubmed |
| pubmed-article:19499960 | pubmed:meshHeading | pubmed-meshheading:19499960... | lld:pubmed |
| pubmed-article:19499960 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19499960 | pubmed:articleTitle | Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study. | lld:pubmed |
| pubmed-article:19499960 | pubmed:affiliation | Department of Cardiology, Hospital Ramón y Cajal, Madrid, Spain. vbarriosa@meditex.es | lld:pubmed |
| pubmed-article:19499960 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19499960 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:19499960 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19499960 | pubmed:publicationType | Multicenter Study | lld:pubmed |
